An Open, Single-Arm, Multi-Center Clinical Study to Evaluate the Safety and Tolerability of Regulatory T Cells (Tregs) In the Treatment of Neurodegenerative Diseases
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Incidence of Treatment Related adverse events (AEs)
研究概览
简要总结
An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
详细描述
This is an open-label, non-randomized, multi-center clinical trial of single-agent NP001 cell injection in patients with with Neurodegenerative diseases (ALS).
After subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, NP001 cell injection. NP001 cell injection are manufactured ex vivo to yield enriched Tregs.
This study is evaluating NP001 cell injection at the dose of 1x E6 cells, 1x E7 cells, and 1x E8 cells/times, with up to 3 times separated by 4 weeks among dosing (intrathecally on Days 1, 29, and 57). Study subjects are then followed for several months to capture safety and efficacy parameters. The total duration of NP001 cell injection and follow-up interval on this protocol is approximately 12-months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following criteria to be eligible for enrollment in this study:
- •Male or female patients aged 18 to 70 years;
- •According to current international diagnostic criteria:
- •ALS: defined by the Gold Coast Diagnostic Criteria (Shefner, 2020) as having a diagnosis of sporadic or familial amyotrophic lateral sclerosis (ALS), diagnosed as a probable, probable, or definite patient with laboratory support according to the World Federation of Neurology El Escorial criteria;
- •If there is a stable dose for more than one month prior to study entry. For example, patients with ALS can continue treatment with riluzole (Rilutek®) and/or edaravone (Radicava®);
- •Patients must have > two weeks after the end of major surgery and after the completion of participation in other research trials;
- •Patients must have recovered from clinical toxicity (CTCAE [5th Edition] toxicity values have resolved to < 2);
- •Serum creatinine less than or equal to 2.0 mg/dL;
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal;
- •Bilirubin < 1.5 (except Gilbert's disease);
- •Lung slow vital capacity (SVC) > 70% of predicted normal;
- •No history of abnormal bleeding tendency;
- •Informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care.
排除标准
- •Subjects with any of the following cannot be enrolled in this study:
- •uncontrolled infection;
- •< 3 drugs do not adequately control hypertension;
- •Documented history of pulmonary embolism within 6 months of enrollment;
- •Clinically significant cardiology, defined as: myocardial infarction, NYHA-graded class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment;
- •Patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis;
- •Seropositive for HIV, hepatitis B or hepatitis C;
- •Pregnant or lactating patients;
- •Patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception;
- •Participation in any other interventional study;
- •Treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. Patient participation in observational/non-interventional clinical studies will be discussed with the Medical Monitor;
- •Prior treatment with ALS gene or cell therapy;
- •History of clinically significant tumor, liver or kidney disease, or other uncontrolled disease;
- •presence of a feeding tube;
- •Current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-Bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs;
- •Subjects who, in the opinion of the investigator, are at significant risk of suicide;
- •Other conditions that the investigator considers unsuitable for enrollment.
研究组 & 干预措施
Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
Regulatory T cell therapy, intrathecal injection
干预措施: Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection) (Biological)
结局指标
主要结局
Incidence of Treatment Related adverse events (AEs)
时间窗: 6 months
Incidence of Treatment Related AEs, AEs of special interest and serious adverse events (SAEs)
Identification of Maximum Tolerated Dose (MTD)
时间窗: 28 days
Incidence of dose-limiting toxicities (DLTs)
次要结局
- Amyotrophic lateral sclerosis functional rating scale- revised (ALSFRS-R)(1 year)
- Rasch Overall ALS Disability Scale (ROADS)(1 year)